Lunai Bioworks Achieves Milestone, Launches Alcohol Use Disorder Program

Lunai Bioworks, an AI-powered drug discovery and biodefense company, has completed a key commercial milestone under its NIH STTR-supported initiative, generating high-resolution behavioral signatures of ethanol exposure and alcohol withdrawal. The company has identified distinct neurobehavioral phenotypes that are not fully addressed by current therapies, highlighting previously underexplored biological mechanisms with strong translational potential. Based on these results, Lunai has initiated a new commercial drug discovery program targeting Alcohol Use Disorder (AUD), affecting approximately 30 million individuals in the US.